TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Sanara MedTech ( (SMTI) ) has issued an update.
On May 19, 2025, Michael D. McNeil announced his retirement from his roles as Chief Accounting Officer and Chief Administrative Officer at Sanara MedTech Inc., effective August 19, 2025. The company is in discussions with McNeil for a consulting role to aid in the transition. Elizabeth B. Taylor, the current Chief Financial Officer, will take over McNeil’s responsibilities as the principal accounting officer.
The most recent analyst rating on (SMTI) stock is a Buy with a $50.00 price target. To see the full list of analyst forecasts on Sanara MedTech stock, see the SMTI Stock Forecast page.
Spark’s Take on SMTI Stock
According to Spark, TipRanks’ AI Analyst, SMTI is a Neutral.
Sanara MedTech’s overall stock score reflects its strong revenue growth and product sales expansion, which are significant positives. However, these are balanced by ongoing concerns in profitability, cash flow management, and increased leverage. The technical analysis suggests neutral market momentum, and the valuation is challenged by negative earnings. The earnings call highlights both growth opportunities and financial challenges, shaping a mixed overall outlook.
To see Spark’s full report on SMTI stock, click here.
More about Sanara MedTech
Average Trading Volume: 28,143
Technical Sentiment Signal: Sell
Current Market Cap: $275.4M
For detailed information about SMTI stock, go to TipRanks’ Stock Analysis page.